Pfizer's prostate cancer drug combination gets U.S. FDA priority review

Talzenna and Xtandi are already ⁠approved in the United States for men whose ‌prostate cancer has spread to other parts of the body and stopped responding to hormone ‌therapy |Image used for representational purpose only | Photo Credit: Getty Images Pfizer said ​on Wednesday the U.S. Food ‌and Drug Administration ​has granted ⁠priority review to its application seeking expanded approval for ‌its prostate cancer treatment combination.The company ‌sought expanded approval ‌to ⁠use a ⁠combination of two approved drugs branded as Talzenna and ​Xtandi in ‌men with metastatic castration-sensitive prostate cancer, whose tumors have acquired gene changes ‌known as HRR ​mutations.Talzenna and Xtandi are already ⁠approved in the United States for men whose ‌prostate cancer has spread to other parts of the body and stopped responding to hormone ‌therapy.For the combination drug, ​Pfizer said the FDA had set ⁠a target decision date in ⁠the last quarter of 2026. Published - July 23, 2026 02:55 pm IST